

Kristina Lindemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430601/publications.pdf>

Version: 2024-02-01

49
papers

946
citations

516710

16
h-index

477307

29
g-index

51
all docs

51
docs citations

51
times ranked

1710
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study. <i>Psycho-Oncology</i> , 2022, 31, 298-305. | 2.3 | 10 |
| 2 | Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 181-188. | 2.5 | 6 |
| 3 | Comparison of the Idylla [®] MSI assay with the Promega [®] MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> . 2022, 480, 1031-1039. | 2.8 | 6 |
| 4 | Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 313-322. | 2.8 | 15 |
| 5 | Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy. <i>Nursing Open</i> , 2022, 9, 1040-1051. | 2.4 | 3 |
| 6 | Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial). <i>Cancer</i> , 2022, 128, 3080-3089. | 4.1 | 7 |
| 7 | AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5611-TPS5611. | 1.6 | 0 |
| 8 | Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer. <i>Cancers</i> , 2021, 13, 1367. | 3.7 | 7 |
| 9 | The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. <i>Acta Oncologica</i> , 2021, 60, 434-443. | 1.8 | 7 |
| 10 | Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1106-1115. | 2.5 | 1 |
| 11 | Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16. | 1.3 | 11 |
| 12 | Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5560-5560. | 1.6 | 1 |
| 13 | Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1248-1259. | 2.5 | 1 |
| 14 | Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking. <i>BMJ Open</i> , 2021, 11, e050930. | 1.9 | 6 |
| 15 | Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. <i>Cancers</i> , 2021, 13, 5848. | 3.7 | 40 |
| 16 | Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002233. | 1.6 | 2 |
| 17 | Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer â€” a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001. | 2.5 | 11 |
| 18 | Preferences for follow up in long-term survivors after cervical cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1253-1259. | 2.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1444-1449. | 2.5 | 3 |
| 20 | Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6057-6057. | 1.6 | 7 |
| 21 | PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. <i>The Cochrane Library</i> , 2019, 2019, CD012160. | 2.8 | 43 |
| 22 | Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO – a focus on surgical aspects. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 181-187. | 2.5 | 9 |
| 23 | Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 97-105. | 2.3 | 3 |
| 24 | AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5601-TPS5601. | 1.6 | 3 |
| 25 | Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1789-1795. | 2.5 | 7 |
| 26 | Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , 2018, 150, 239-246. | 1.4 | 32 |
| 27 | End of life care in gynaecological cancer patients: A population-based study of cancer deaths from the Swedish Register of Palliative Care.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10028-10028. | 1.6 | 0 |
| 28 | Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). <i>British Journal of Cancer</i> , 2017, 116, 455-463. | 6.4 | 33 |
| 29 | Enhanced Recovery After Surgery for Suspected Ovarian Malignancy. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1046-1050. | 2.5 | 11 |
| 30 | Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study. <i>Acta Oncologica</i> , 2017, 56, 1302-1309. | 1.8 | 26 |
| 31 | Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726. | 1.5 | 44 |
| 32 | Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1274-1282. | 2.5 | 32 |
| 33 | A Call for New Communication Channels for Gynecological Oncology Trainees. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 620-626. | 2.5 | 2 |
| 34 | The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. <i>Neuro-Oncology</i> , 2016, 19, now272. | 1.2 | 29 |
| 35 | L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. <i>BMC Cancer</i> , 2016, 16, 596. | 2.6 | 25 |
| 36 | PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. <i>The Cochrane Library</i> , 2016, , . | 2.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464. | 1.4 | 17 |
| 38 | Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study). <i>European Journal of Epidemiology</i> , 2016, 31, 95-98. | 5.7 | 5 |
| 39 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5553-5553. | 1.6 | 1 |
| 40 | Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey. <i>Gynecologic Oncology</i> , 2015, 139, 476-480. | 1.4 | 16 |
| 41 | Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). <i>BMC Cancer</i> , 2014, 14, 68. | 2.6 | 30 |
| 42 | Prediagnostic diabetes, body mass index, and survival of endometrial cancer: A prospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5601-5601. | 1.6 | 0 |
| 43 | Long-Term Outcomes After Pelvic Radiation for Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3951-3956. | 1.6 | 86 |
| 44 | Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5008-5008. | 1.6 | 5 |
| 45 | Endometrial cancer incidence trends in Norway during 1953â€“2007 and predictions for 2008â€“2027. <i>International Journal of Cancer</i> , 2010, 127, 2661-2668. | 5.1 | 42 |
| 46 | Serum lipids and endometrial cancer risk: Results from the HUNTâ€“H study. <i>International Journal of Cancer</i> , 2009, 124, 2938-2941. | 5.1 | 51 |
| 47 | A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer. <i>Scientific World Journal, The</i> , 2008, 8, 905-908. | 2.1 | 0 |
| 48 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. <i>International Journal of Cancer</i> , 2005, 113, 678-682. | 5.1 | 227 |
| 49 | Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?. <i>Oncologist</i> , 2005, 10, 480-492. | 3.7 | 19 |